OUTREACH: Phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.
Linhares Y, Freytes CO, Cherry M, Bachier C, Maris MB, Hoda D, Varela JC, Bellomo C, Cross S, Essell JH, Fanning S, Terebelo H, Yimer HA, Courtright J, Sharman JP, Kostic A, Vedal M, Ogasawara K, Avilion A, Espinola R, Yuan B, Mattar B.
Linhares Y, et al. Among authors: cherry m.
Blood Adv. 2024 Sep 30:bloodadvances.2024013254. doi: 10.1182/bloodadvances.2024013254. Online ahead of print.
Blood Adv. 2024.
PMID: 39347584